American Association for Cancer Research
Browse
15357163mct171091-sup-191982_2_supp_4495781_p2b3bk.xlsx (120.03 kB)

Supplementary Tables S1-S4 from Impact of Chemical-Induced Mutational Load Increase on Immune Checkpoint Therapy in Poorly Responsive Murine Tumors

Download (120.03 kB)
dataset
posted on 2023-04-03, 16:03 authored by Elizabeth A. Kuczynski, Janna Krueger, Annabelle Chow, Ping Xu, Shan Man, Yogi Sundaravadanam, Jessica K. Miller, Paul M. Krzyzanowski, Robert S. Kerbel

Supplementary Table S1 lists missense mutations in mutagenized EMT-6/P variant cells. Supplementary Table S2 lists driver mutations in mutagenized EMT-6/P variant cells. Supplementary Table S3 lists the results of functional annotation clustering of mutagenized EMT-6/P variants. Supplementary Table S4 tabulates numerically growth rates of mutagenized variants in syngeneic and immunodeficient mice.

Funding

CBCF

CIHR

History

ARTICLE ABSTRACT

A recurring historic finding in cancer drug development is encouraging antitumor effects observed in tumor-bearing mice that fail to translate into the clinic. An intriguing exception to this pattern is immune checkpoint therapy, as the sustained tumor regressions observed in subsets of cancer patients are rare in mice. Reasoning that this may be due in part to relatively low mutational loads of mouse tumors, we mutagenized transplantable mouse tumor cell lines EMT-6/P, B16F1, RENCA, CT26, and MC38 in vitro with methylnitro-nitrosoguanidine (MNNG) or ethylmethane sulfonate (EMS) and tested their responsiveness to PD-L1 blockade. Exome sequencing confirmed an increase in somatic mutations by mutagen treatment, an effect mimicked in EMT-6 variants chronically exposed in vivo to cisplatin or cyclophosphamide. Certain mutagenized variants of B16F1, EMT-6/P, CT26, and MC38 (but not RENCA) were more immunogenic than their parents, yet anti-PD-L1 sensitization developed only in some EMT-6/P and B16F1 variants. Treatment response patterns corresponded with changes in immune cell infiltration and especially increases in CD8+ T cells. Chronically cisplatin-exposed EMT-6 variants were also more responsive to anti-PD-L1 therapy. Although tumor PD-L1 expression was upregulated in in vivo chemotherapy-exposed variants, PD-L1 expression levels were not consistently associated with anti-PD-L1 treatment activity across mutagenized or chemotherapy-exposed variants. In summary, mutagenized and more immunogenic mouse tumors were not universally sensitized to PD-L1 blockade. Chemically mutagenized variants may be useful to evaluate the impact of immunologically “hot” or “cold” tumors with a high mutational load, to which certain chemotherapy agents may contribute, on immunotherapy outcomes. Mol Cancer Ther; 17(4); 869–82. ©2018 AACR.